公开(公告)号：US20220142947A1

公开(公告)日：2022-05-12

申请号：US17565556

申请日：2021-12-30

申请人： Albert Einstein College of Medicine

发明人： Joel M. Friedman

IPC分类号： A61K31/12 ,  A61K31/352 ,  A61K31/4375 ,  A61K31/05 ,  A61K31/593 ,  A61K47/10 ,  A61K47/12 ,  A61K9/00 ,  A61P37/06 ,  A61K9/06

摘要： A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.

公开(公告)号：US20220125745A1

公开(公告)日：2022-04-28

申请号：US17429791

申请日：2019-11-29

申请人： HAIM BIO CO., LTD.

发明人： Yong Bae KIM ,  Sun Young PARK ,  Kyung Seop YUN ,  Min Hee JANG ,  Se Young JEONG ,  Eun Jeong KIM ,  Jin Sam LEE ,  Hong Yeoul KIM

IPC分类号： A61K31/155 ,  A23L33/10 ,  A61K31/4409 ,  A61K31/4375 ,  A61K31/5377

摘要： The present invention relates to a pharmaceutical composition for administration in combination with a drug that causes acidosis. Acidosis occurs due to disrupted acid-base balance caused in a case where a large amount of acid is produced and accumulated in the body. There are many cases where acidosis occurs as a side effect associated with drugs for treating various diseases, which poses problems. The pharmaceutical composition of the present invention not only allows the intended purpose, for which a drug that causes acidosis is administered, to be maintained but also has a remarkable effect in decreasing the concentration of acid accumulated in an organism due to administration of the drug that causes acidosis. Thus, the pharmaceutical composition is expected to be widely used in the fields of medicine and health.

公开(公告)号：US20220117916A1

公开(公告)日：2022-04-21

申请号：US17238459

申请日：2021-04-23

申请人： SafeRx Pharmaceuticals, LLC

发明人： Michael Presti

IPC分类号： A61K31/145 ,  A61K31/275 ,  A61K31/04 ,  A61K31/7048 ,  A61K31/4164 ,  A61K31/198 ,  A61K31/55 ,  A61K31/137 ,  A61K31/4184 ,  A61K31/11 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/5025 ,  A61K31/4439 ,  A61P25/32

摘要： A method is provided for reducing a risk that a subject will experience a medically-related adverse event associated with inappropriate consumption of alcohol concurrent with the taking of a nonbenzodiazepine benzodiazepine receptor agonist (NBBRA). In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more NBBRAs, and an effective amount of one or more aldehyde dehydrogenase inhibitors (ALDIs), to provide the desired effects of the NBBRA in conjunction with a substance that prevents or deters concurrent alcohol consumption, thereby reducing the risk of the subject experiencing an alcohol-induced medically-related adverse event. Also disclosed are the combination products that include the effective amount of one or more NBBRAs and the effective amount of one or more ALDIs.

公开(公告)号：US20220105033A1

公开(公告)日：2022-04-07

申请号：US17423600

申请日：2020-01-23

申请人： BEIGENE, LTD.

发明人： Guoliang ZHANG ,  Changyou ZHOU ,  Huangbin SUN

IPC分类号： A61K9/10 ,  A61K47/38 ,  A61K9/14 ,  A61K31/4375

摘要： Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b]benzofuran-1 yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.

公开(公告)号：US20220087971A1

公开(公告)日：2022-03-24

申请号：US17330848

申请日：2021-05-26

申请人： BACH BIOSCIENCES, LLC

发明人： William W. Bachovchin ,  Hung-sen Lai ,  David G. Sanford ,  Sarah E. Poplawski ,  Wengen Wu

IPC分类号： A61K31/337 ,  A61K47/54 ,  A61K47/64 ,  A61K31/4155 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/517 ,  A61K31/519 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7068

摘要： Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.

公开(公告)号：US20220064118A1

公开(公告)日：2022-03-03

申请号：US17229012

申请日：2021-04-13

申请人： The Trustees of the University ofPennsylvania

发明人： Ravi K. Amaravadi ,  Jeffrey D. Winkler

IPC分类号： C07D215/46 ,  A61K31/4706 ,  A61K31/4709 ,  C07D401/12 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/704 ,  A61K31/7056

摘要： The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.

公开(公告)号：US11261205B2

公开(公告)日：2022-03-01

申请号：US16908244

申请日：2020-06-22

申请人： Morphochem GmbH

发明人： Thomas Kapsner ,  Axel Dalhoff ,  Thomas Gramatte

IPC分类号： C07F9/653 ,  A61K31/4709 ,  A61K31/4375 ,  A61P31/04 ,  A61P31/00 ,  A61P1/12 ,  A61P1/00

摘要： The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.

公开(公告)号：US11253503B2

公开(公告)日：2022-02-22

申请号：US16335754

申请日：2017-09-22

申请人： Washington University ,  Disarm Therapeutics, Inc.

发明人： Jeffrey Milbrandt ,  Kow Essuman ,  Yo Sasaki ,  Aaron DiAntonio ,  Xianrong Mao ,  Rajesh Devraj ,  Raul Eduardo Krauss ,  Robert Owen Hughes

IPC分类号： A61K31/4439 ,  A61K47/55 ,  A61K47/52 ,  A61P25/28 ,  A61K33/243 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30

摘要： The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

公开(公告)号：US11241418B2

公开(公告)日：2022-02-08

申请号：US16796448

申请日：2020-02-20

申请人： INVENTISBIO SHANGHAI LTD.

发明人： Xing Dai ,  Yueheng Jiang

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K45/06

摘要： Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

公开(公告)号：US20220023274A1

公开(公告)日：2022-01-27

申请号：US17311669

申请日：2019-12-16

申请人： S&R FARMACEUTICI S.P.A.

发明人： Bernard FIORETTI ,  Lucio LEONARDI

IPC分类号： A61K31/4375 ,  A61K31/05 ,  A23L33/10 ,  A61K45/06 ,  A61P3/06

摘要： A pharmaceutical or nutraceutical composition or a food supplement including a mixture of berberine and resveratrol for use in treatment and/or control of dyslipidemia is described, wherein resveratrol is co-precipitated or supported on a salt or hydroxide of a divalent or trivalent metal.